Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Inhibition of WNT signaling in the bone marrow niche prevents the development of MDS in the Apc del/ + MDS mouse model

Angela Stoddart, Jianghong Wang, Chunmei Hu, Anthony A. Fernald, Elizabeth M. Davis, Jason X. Cheng, Michelle M. Le Beau

Blood (2017) 129 (22): 2959–2970.

https://doi.org/10.1182/blood-2016-08-736454

Published: 2017

Includes: Supplemental data

Journal Articles

Inhibition of Canonical WNT Signaling in the Bone Marrow Niche Prevents the Development of Disease in a Mouse MDS Model with Apc Haploinsufficiency

Angela Stoddart, PhD, Jianghong Wang, MD, Chunmei Hu, MD, Anthony A. Fernald, BS, Elizabeth M. Davis, BS, Jason X. Cheng, MDPhD, Michelle M. Le Beau, PhD

Blood (2016) 128 (22): 1129.

https://doi.org/10.1182/blood.V128.22.1129.1129

Published: 2016

Journal Articles

Bromodomain and Extra-Terminal Motif Proteins (BETs) Mediate 5-Azacitidine Resistance in Myeloid Leukemia through Recruitment of an Active RNA Polymerase II Complex

Li Chen, MD PhD, Yuan Li, MD, Ming Yue, PhD, Adam Cloe, MD PhD, Michelle M. Le Beau, PhD, Chuan He, PhD, Richard A. Larson, MD, James W. Vardiman, MD, Jason X. Cheng, MD PhD

Blood (2016) 128 (22): 746.

https://doi.org/10.1182/blood.V128.22.746.746

Published: 2016

Journal Articles

Identification of Specific Hnrnps As Novel Therapeutic Targets and Responsive Indicators of KPT330 (selinexor) in Leukemia

Adam Cloe, MD PhD, Li Chen, MD PhD, Yuan Li, MD, Hongtao Liu, MD PhD, Jason X. Cheng, MD PhD

Blood (2016) 128 (22): 1657.

https://doi.org/10.1182/blood.V128.22.1657.1657

Published: 2016

Journal Articles

FLT3 Inhibitors for the Treatment of Acute Myeloid Leukemia: An Evaluation of Efficacy of Target Inhibition and Relationship to Disease Progression

Adam Cloe, MD PhD, Richard A. Larson, MD, Jason X. Cheng, MDPhD

Blood (2015) 126 (23): 4940.

https://doi.org/10.1182/blood.V126.23.4940.4940

Published: 2015

Journal Articles

Epigenetic Modifying Drugs Inhibit MDS/AML Cell Growth through Selective Disruption of the Interactions Between Lineage-Determining Transcription Factors and DNA/Histone Modifiers

Yuan Li, MD, Ming Yue, PhD, John Anastasi, MD, Jeffery Q Shen, PhD, Yali Dou, PhD, Richard A. Larson, MD, James W. Vardiman, MD, Jason X. Cheng, MDPhD

Blood (2015) 126 (23): 3853.

https://doi.org/10.1182/blood.V126.23.3853.3853

Published: 2015

Journal Articles

Cytotoxic Exposure to Both Hematopoietic Stem and Progenitor Cells and the Bone Marrow Niche Cooperate to Promote Leukemogenesis in a Mouse Model of Therapy-Related Myeloid Neoplasms with a Del(5q)

Angela Stoddart, PhD, Jianghong Wang, MD, Chunmei Hu, MD, Anthony A. Fernald, BS, Elizabeth M. Davis, BS, Jason X. Cheng, MDPhD, Michelle M. Le Beau, PhD

Blood (2015) 126 (23): 357.

https://doi.org/10.1182/blood.V126.23.357.357

Published: 2015

Journal Articles

Indolent T-cell lymphoproliferative disease of the gastrointestinal tract

Anamarija M. Perry, Roger A. Warnke, Qinglong Hu, Philippe Gaulard, Christiane Copie-Bergman, Serhan Alkan, Huan-You Wang, Jason X. Cheng, Chris M. Bacon, Jan Delabie, Erik Ranheim, Can Kucuk, XiaoZhou Hu, Dennis D. Weisenburger, Elaine S. Jaffe, Wing C. Chan

Blood (2013) 122 (22): 3599–3606.

https://doi.org/10.1182/blood-2013-07-512830

Published: 2013

Includes: Supplemental data

Journal Articles

Disease-Associated Chromatin Conformation and Therapeutic Implications In Leukemia

Jason X Cheng, MD, PhD, John Anastasi, MD, James W. Vardiman, MD

Blood (2013) 122 (21): 4892.

https://doi.org/10.1182/blood.V122.21.4892.4892

Published: 2013

Journal Articles

A Novel Epigenetic Mechanism in the Pathogenesis of Myelodysplastic Syndrome (MDS)

Jason X Cheng, MD, PhD, John Anastasi, MD, Jeffery Q Shen, PhD, Kenneth Q Watanabe, Edward Grimley, Erica Kleinbrink, Randal Knibbs, PhD, James W. Vardiman, MD

Blood (2011) 118 (21): 2783.

https://doi.org/10.1182/blood.V118.21.2783.2783

Published: 2011

Journal Articles

Molecular Mechanisms Underlying the Regulation of Alternate Macrophage and Neutrophil Gene Programs by the Egr Transcription Factors

Jason X Cheng, MD, PhD, Peter Laslo, PhD, Chauncey Spooner, PhD, Eric Bertolino, Harinder Singh, PhD

Blood (2008) 112 (11): 4773.

https://doi.org/10.1182/blood.V112.11.4773.4773

Published: 2008

NARROW

Inhibition of WNT signaling in the bone marrow niche prevents the development of MDS in the Apc del/ + MDS mouse model

Inhibition of Canonical WNT Signaling in the Bone Marrow Niche Prevents the Development of Disease in a Mouse MDS Model with Apc Haploinsufficiency

Bromodomain and Extra-Terminal Motif Proteins (BETs) Mediate 5-Azacitidine Resistance in Myeloid Leukemia through Recruitment of an Active RNA Polymerase II Complex

Identification of Specific Hnrnps As Novel Therapeutic Targets and Responsive Indicators of KPT330 (selinexor) in Leukemia

FLT3 Inhibitors for the Treatment of Acute Myeloid Leukemia: An Evaluation of Efficacy of Target Inhibition and Relationship to Disease Progression

Epigenetic Modifying Drugs Inhibit MDS/AML Cell Growth through Selective Disruption of the Interactions Between Lineage-Determining Transcription Factors and DNA/Histone Modifiers

Cytotoxic Exposure to Both Hematopoietic Stem and Progenitor Cells and the Bone Marrow Niche Cooperate to Promote Leukemogenesis in a Mouse Model of Therapy-Related Myeloid Neoplasms with a Del(5q)

Indolent T-cell lymphoproliferative disease of the gastrointestinal tract

Disease-Associated Chromatin Conformation and Therapeutic Implications In Leukemia

A Novel Epigenetic Mechanism in the Pathogenesis of Myelodysplastic Syndrome (MDS)

Molecular Mechanisms Underlying the Regulation of Alternate Macrophage and Neutrophil Gene Programs by the Egr Transcription Factors

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only